Global Psoriatic Arthritis Treatment Market 2019 Overview by: Novartis AG, Pfizer Inc., Amgen, Merck by 2026
Global Psoriatic Arthritis Treatment Market is likely to gain momentum from a rise in the prevalence of psoriatic arthritis across the world. According to a published report by Fortune Business Insight, titled, “Psoriatic Arthritis Treatment Market: Global Market Analysis, Insights, and Forecast, 2018-2026,” the global psoriatic arthritis treatment market was valued at US$ 5,793.3 Mn in 2018. The market is anticipated to reach US$ 12,175.2 Mn by 2026, exhibiting a CAGR of 8.5% between 2018-2026. Moreover, the report suggests that the lifestyles of people are slowly becoming stressful, leading to the overstimulation of immune system.— The
This in turn, is resulting in an increasing incidence of psoriatic arthritis in developing as well as developed countries. All these factors are expected to contribute to the global psoriatic arthritis treatment market growth during the forecast period.
Key questions answered in the Psoriatic Arthritis Treatment Market report:
• What will the market growth rate of Psoriatic Arthritis Treatment market in 2026?
• What are the key factors driving the Global Psoriatic Arthritis Treatment market?
• What are sales, revenue, and price analysis of top manufacturers of Psoriatic Arthritis Treatment market?
• Who are the distributors, traders and dealers of Psoriatic Arthritis Treatment market?
• Who are the key vendors in Psoriatic Arthritis Treatment market space?
• What are the Psoriatic Arthritis Treatment market opportunities and threats faced by the vendors in the Asia Psoriatic Arthritis Treatment market?
• What are sales, revenue, and price analysis by types, application and regions of Psoriatic Arthritis Treatment market?
• What are the market opportunities, market risk and market overview of the Psoriatic Arthritis Treatment market?
Get PDF Brochure of this Report@ https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/psoriatic-arthritis-treatment-market-101066
Increasing Adoption of Biological Therapies to Favor Growth of Biological Disease Modifying Anti-Rheumatic Drugs Segment
The report classifies the global psoriatic arthritis treatment market on the bases of drug class, route of administration, distribution channel, and geography. By drug class, the global market is grouped into Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-steroidal Anti-inflammatory Drugs (NSAIDS), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), and others. Amongst these, the Biologic Disease Modifying Anti-Rheumatic Drugs segment had gained 63.4% global psoriatic arthritis treatment market share in the year 2018.
Fortune Business Insights predicts that the segment will remain in the dominant position throughout the forecast period owing to the rising adoption of biological therapies. This is because such therapies are very efficient in managing psoriatic arthritis. By route of administration, the market is divided into parenteral, oral, and topical. The parenteral route of administration is anticipated to procure major share of the global psoriatic arthritis treatment market. This is because most of the biological products are only provided by parenteral route.
Some major points from Table of Content:
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1. Prevalence of Psoriatic Arthritis for Key Countries/Region
4.2. Recent Industry Developments Such as Partnerships, Mergers & Acquisitions, New Product Launches Etc.
4.3. Pipeline Analysis for Key Companies
4.4. Regulatory Framework by Key Countries
4.5. Global Reimbursement Scenario
5. Global Psoriatic Arthritis Treatment Market Analysis, Insights and Forecast, 2015-2026
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Drug Class
5.2.1. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
5.2.2. Non-biologic Disease Modifying Anti-Rheumatic Drugs
5.2.3. Biologic Disease Modifying Anti-Rheumatic Drugs
5.3. Market Analysis, Insights and Forecast – By Route of Administration
5.4. Market Analysis, Insights and Forecast – By Distribution Channel
5.4.1. Hospital Pharmacies
5.4.2. Retail Pharmacies
5.4.3. Online Pharmacies
5.5. Market Analysis, Insights and Forecast – By Region
5.5.1. North America
5.5.3. Asia pacific
5.5.4. Latin America
5.5.5. Middle East & Africa
6. North America Psoriatic Arthritis Treatment Market Analysis, Insights and Forecast, 2015-2026
6.1. Key Findings / Summary
6.2. Market Analysis – By Drug Class
6.2.1. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
6.2.2. Non-biologic Disease Modifying Anti-Rheumatic Drugs
6.2.3. Biologic Disease Modifying Anti-Rheumatic Drugs
6.3. Market Analysis – By Route of Administration
6.4. Market Analysis – By Distribution Channel
6.4.1. Hospital Pharmacies
6.4.2. Retail Pharmacies
6.4.3. Online pharmacies
6.5. Market Analysis – By Country
11. Competitive Analysis
11.1. Key Industry Developments
11.2. Global Market Share Analysis (2018)
11.3. Competition Dashboard
11.4. Comparative Analysis – Major Players
11.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
11.5.1. AbbVie Inc.
11.5.2. Novartis AG
11.5.3. Johnson & Johnson Services, Inc.
11.5.4. Pfizer Inc.,
11.5.5. LEO Pharma A/S
11.5.6. Merck & Co., Inc.
11.5.7. Amgen Inc.
11.5.8. Eli Lilly and Company
11.5.9. CELGENE CORPORATION
11.5.10. UCB S.A.
11.5.11. Sun Pharmaceutical Industries Ltd.
11.5.12. Other prominent players
12. Strategic Recommendation
Major Market Players, such as AbbVie Inc. and Pfizer Inc. Focus on Achieving Drug Approvals to Gain Competitive Edge
AbbVie Inc., a publicly traded biopharmaceutical company, based in the U.S., announced in March 2019 that the Japanese Ministry of Health, Labor and Welfare (MHLW) approved its product called SKYRIZI (risankizumab). SKYRIZI is an interleukin-23 (IL-23) inhibitor that is used for the treatment of erythrodermic psoriasis, plaque psoriasis, psoriatic arthritis, and generalized pustular psoriasis in those adults who have difficulties in having an inadequate response to conventional therapies. SKYRIZI also causes improvements in the signs and symptoms of immune-mediated and chronic diseases.
Earlier, in December 2017, Eli Lilly and Company, a pharmaceutical company headquartered in Indiana, announced that the USFDA approved Taltz (ixekizumab) injection 80 mg/ml. It will be used for the treatment of adults with active psoriatic arthritis (PsA).
Fortune Business Insights profiles some of the prominent market players that are currently operating in the global psoriatic arthritis treatment market. They are AbbVie Inc., Merck & Co., Inc., UCB S.A., Novartis AG, Celgene Corporation, Johnson & Johnson Services, Inc., Sun Pharmaceutical Industries Ltd., Pfizer Inc., Eli Lilly and Company, LEO Pharma A/S, Amgen Inc., and other prominent market players.
More Trending Topics From Fortune Business Insights@
Release ID: 88911742